Core C (Cell Processing and Immune Monitoring Core): Project Summary/Abstract The Cell Processing and Immune Monitoring Core (Core C) will support each of the projects in this proposal by leveraging existing infrastructure at Stanford University and assisting project investigators in the standardized use of these resources. Core C provides technical expertise and regulatory support in the preparation of cellular products for clinical trials including product manipulation and characterization, quality management, and process documentation. This support will be provided by the Stanford Health Care Cellular Therapy Facility (CTF). By offsetting development and manufacturing costs, and providing support to a dedicated cellular pharmacist, Core C provides processing for cell-based therapeutics compliant with both current Good Tissue Practices (cGTP) and current Good Manufacturing Practices (cGMP). An important function of Core C is to facilitate interaction between the clinical and research arms of the program by assisting with the translational development of cell- based therapies from pre-clinical models. Core C facilitates tissue banking and manages sample distribution to investigators. Through a collaborative arrangement between the CTF and the Stanford Spectrum Biobank, Core C will support a project-based tissue bank including collection of material from donor grafts, cell products and pre- and post-transplant blood specimens for long term storage and use by project teams. Core C provides standardized immune monitoring of the T cell receptor repertoire and facilitates use of other specialized immune assays through existing institutional shared core facilities. Building on our past Core C optimization of a platform for measuring TCR Vb CDR3 repertoire, we will provide standardized TCR sequencing to each project, with a goal of having the donor graft, experimental cell product, and post-transplant samples evaluated in the same manner for each project. We will also assist each project in accessing and using the resources for immune monitoring available through the Human Immune Monitoring Core (HIMC) and genomics service centers. In summary, this Core serves to help integrate the PPG into the large infrastructure established at Stanford for conducting and scientifically monitoring cellular therapy clinical trials, thus avoiding the unnecessary duplication of resources and enhancing efficiency.

Public Health Relevance

Core C (Cell Processing and Immune Monitoring Core): Project Narrative The Cell Processing and Immune Monitoring Core (Core C) uses state of the art facilities, service centers and specific technologies to support investigators of the Program Project Grant by providing dedicated support for cell therapy, biobanking and immune monitoring in a highly integrated and directed way. Centralized performance of biobanking and immune monitoring techniques will avoid duplication of effort in the program and ensure timely, efficient, comparable and consistently high quality results.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
2P01CA049605-29A1
Application #
9793136
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2019-09-01
Budget End
2020-08-31
Support Year
29
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Stanford University
Department
Type
DUNS #
009214214
City
Stanford
State
CA
Country
United States
Zip Code
94305
Zerboni, Leigh; Sung, Phillip; Sommer, Marvin et al. (2018) The C-terminus of varicella-zoster virus glycoprotein M contains trafficking motifs that mediate skin virulence in the SCID-human model of VZV pathogenesis. Virology 523:110-120
Muffly, Lori; Sheehan, Kevin; Armstrong, Randall et al. (2018) Infusion of donor-derived CD8+ memory T cells for relapse following allogeneic hematopoietic cell transplantation. Blood Adv 2:681-690
Tavallaee, Mahkam; Steiner, David F; Zehnder, James L et al. (2018) Coexistence of BRAF V600E and TERT Promoter Mutations in Low-grade Serous Carcinoma of Ovary Recurring as Carcinosarcoma in a Lymph Node: Report of a Case. Int J Gynecol Pathol :
Du, Jing; Paz, Katelyn; Thangavelu, Govindarajan et al. (2017) Invariant natural killer T cells ameliorate murine chronic GVHD by expanding donor regulatory T cells. Blood 129:3121-3125
Spinner, Michael A; Fernández-Viña, Marcelo; Creary, Lisa E et al. (2017) HLA-mismatched unrelated donor transplantation using TLI-ATG conditioning has a low risk of GVHD and potent antitumor activity. Blood Adv 1:1347-1357
Costa, Helio A; Neal, Joel W; Bustamante, Carlos D et al. (2017) Identification of a Novel Somatic Mutation Leading to Allele Dropout for EGFR L858R Genotyping in Non-Small Cell Lung Cancer. Mol Diagn Ther 21:431-436
Chen, Yi-Bin; Efebera, Yvonne A; Johnston, Laura et al. (2017) Increased Foxp3+Helios+Regulatory T Cells and Decreased Acute Graft-versus-Host Disease after Allogeneic Bone Marrow Transplantation in Patients Receiving Sirolimus and RGI-2001, an Activator of Invariant Natural Killer T Cells. Biol Blood Marrow Transplant 23:625-634
Xu, Liwen; You, Xiaoqing; Zheng, PingPing et al. (2017) Methodologic Considerations in the Application of Next-Generation Sequencing of Human TRB Repertoires for Clinical Use. J Mol Diagn 19:72-83
Pierini, Antonio; Alvarez, Maite; Negrin, Robert S (2016) NK Cell and CD4+FoxP3+ Regulatory T Cell Based Therapies for Hematopoietic Stem Cell Engraftment. Stem Cells Int 2016:9025835
Nybakken, Grant E; Bala, Rajeev; Gratzinger, Dita et al. (2016) Isolated Follicles Enriched for Centroblasts and Lacking t(14;18)/BCL2 in Lymphoid Tissue: Diagnostic and Clinical Implications. PLoS One 11:e0151735

Showing the most recent 10 out of 307 publications